# US 2014/0193827 A1 · Characterizing a glatiramer acetate related drug product > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0193827 A1 - Document ID: US20140193827A1 - Status: Published application - Kind: A1 - Application number: 14/147,167 - Filed: 2014-01-03 - Published: 2014-07-10 - Earliest claimed: 2013-01-04 - Assignees: Teva Pharmaceutical Industries Ltd. - Inventors: Rivka Schwartz; Shlomo Bakshi; Kevin Daniel Fowler; Fadi George Towfic; Jason Michael Funt; Benjamin James Zeskind; Maksym Artomov - Web page: https://patentgrep.com/patent/US20140193827A1 ## CPC - G01N 33/5023: {on expression patterns} - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The present invention provides a process for characterizing a glatiramer acetate related drug substance or drug product comprising the steps of: a) obtaining a batch of the glatiramer acetate related drug substance or drug product; b) immunizing a mammal with a predetermined amount of a glatiramer acetate related drug substance or drug product; c) preparing a culture of cells from the mammal of step b) at a predetermined time after immunization; d) incubating cells from the culture of step c) with a predetermined amount of the glatiramer acetate drug related substance or drug product of step a); and e) determining the level of expression of at least one gene disclosed herein or determining the level of biological activity of the cells of step c) as disclosed herein, thereby characterizing the glatiramer acetate related drug substance or drug product of step a). ## Claims ### Claim 1 A process for characterizing a glatiramer acetate related drug substance or drug product comprising the steps of: a) obtaining a batch of the glatiramer acetate related drug substance or drug product; b) immunizing a mammal with a predetermined amount of a glatiramer acetate related drug substance or drug product; c) preparing a culture of cells from the mammal of step b) at a predetermined time after immunization; d) incubating cells from the culture of step c) with a predetermined amount of the glatiramer acetate drug related substance or drug product of step a); and e) determining the level of expression of at least one gene selected from the group consisting of genes regulated by glatiramer acetate drug substance or drug product in Gene Expression Omnibus accession number GSE40566; determining the level of expression of at least one gene selected from the group consisting of Ecm1, Pres1, Pdlim4, Gpr83, Ifng, Il24, LOC100046608, Gm590, Gpr114, Tmie, Rasgrp1, Myo6, Pfkp, Usp18, Arl4c, Als2cl, 2810410P22Rik, Arl5a, Gbp2, Rasgrp1, Ankrd37, Tpi1, 4930583H14Rik, Ifit3, LOC667370, Klhdc1, Cd247, Igfbp4, Oas2, Bcl11b, Fscn1, Ctsg, Mpo, Prtn3, Lyzs, Emr1, Chi3l1, Anxa3, Hp, Lyz2, Lyz, Fer1l3, Sirpa, Cd63, Clec4n, Clec4d, EG433016, Stfa1, Chi3l3 Ngp, S100a8, S100a9, Clecsf9, Saa3, 5033414K04Rik, Slc7a11, Slpi, Cd14, Fpr2, Fcgr3, F10, Gpnmb, Tgfbi, Mmp14, Slcllal, C3, Gpr84, Acta2, Lcn2, Hmox1, Tsab1, Ccl4, Il2, Inhba, Cxcl1, Serpinb2, Upp1, Gpr109a, Gp38, Il1b, Cxcl2, Il1a, Ccl3, 6720418B01Rik, 5830496L11Rik, Cd8b1, Fcgrt, LOC385615 and Scml4; determining the level of expression of at least one gene selected from the group consisting of CD40, CD86, GATA3, HLA-DMA, HLA-DMB, ICOS, IFNG, IFNGR2, IL2, IL13, IL4, IL18, IL12RB1, IL17A, IL17F, IL18R1, IL2RA, IL2RG, IL4R, IL6R, TBX21, TGFBR2, TNF, FOXP3, IL10RB, KLRD1, CD69, LTB, CD83, PRF1, CAMK2D, LTA, FSCN1, TLR7, CSF2, CCR7, FASLG, IL1A, CCL5, CD8B, CXCL10, TLR2, CCL4, TLR7, IGHA1, IL24, SOCS1, OAS1, JAK1, PTPN2, IFITM1, IF135, STAT2, BCL2, MVD, FDPS, SQLE, NSDHL, DHCR24, Acat2/Acat3, MSMO1, LSS, CYP51A1, NFKBIE, PIK3R1, PPP3CC, CD3D, IL2RB, PTEN, CD3G, ICOS, CAMK2D, NFAT5, LAT, ITK, H2-M2, FASLG, LIF, IGRA1, PRKACB, SGK1, MAPK11, TSC22D3, JUN, FKBP5, ADRB2, MAP3K1, MAPK12, POU2F1, SMARCA2, CDKN1A, TGFB3, HSP90AA1, DHCR24, CCR5, and CXCL9; determining the level of expression of at least one gene selected from the group consisting of Foxp3, Il2, Il1a, Il1b, C3, S100a8, S100a9, Cxcl2, Cxcl3, Ccl4, Ccl3 and Cd14; determining the level of expression of at least one gene selected from the group consisting of the genes presented in Table 8; determining the level of expression of at least one gene selected from the group consisting of the genes presented in Table 10; determining the level of expression of at least one gene selected from the group consisting of FoxP3, GPR83, CD14, TLR2, IFNG, CD40 and IL1B; determining the level of expression of at least one gene selected from the group consisting of the genes presented in Table 12; or determining gene set enrichment analysis for genes associated with at least one cell type selected from the group consisting of FoxP3+ CD4+ T cells, CD4+ T cells CD8+ T cells, gamma delta T cells, natural killer T cells, CD4+ CD8+ T cells, macrophage cells, monocyte cells stromal cells, multi-lineage progenitor cells, dendritic cells, fibroblastic reticular cells, fibroblasts and granulocytes, or determining the level of biological activity of the cells of step c) selected from the group consisting of, immune response to antigen presenting cells, differentiation of effector lymphocytes, suppression of T lymphocytes, activation of Foxp3 positive regulatory T cells, expansion of mononuclear leukocytes, proliferation of T lymphocytes, expansion of lymphocytes, differentiation of naïve lymphocytes, inflammatory response, adhesion of immune cells, cell movement, migration of cells, chemotaxis of cells, cell movement of phagocytes, chemotaxis of monocytes, cell movement of monocytes and fever, thereby characterizing the glatiramer acetate related drug substance or drug product of step a). ### Claim 2 (canceled) ### Claim 3 (depends on 1) A process for discriminating between glatiramer acetate related drug substances or drug products comprising the steps of: i) characterizing two or more glatiramer acetate related drug substances or drug products according to the process of claim 1 to obtain characteristics of each of the glatiramer acetate related drug substances or drug products; and ii) comparing the characteristics of the glatiramer acetate related drug substances or drug products obtained in step i), thereby discriminating between the glatiramer acetate related drug substances or drug products. ### Claim 4 (depends on 1) The process of claim 1, wherein the mammal is a rodent. ### Claim 5 (depends on 1) The process of claim 1, wherein the culture of step c) is a primary culture. ### Claim 6 (depends on 1) The process of claim 1, wherein the glatiramer acetate related drug substance or drug product of step a) is glatiramer acetate drug substance or drug product, or a glatiramer acetate related drug substance or drug product other than glatiramer acetate drug substance or drug product. ### Claim 7 (canceled) ### Claim 8 (depends on 1) The process of claim 1, wherein the glatiramer acetate related drug substance or drug product of step b) is glatiramer acetate drug substance or drug product, or a glatiramer acetate related drug substance or drug product other than glatiramer acetate drug substance or drug product. ### Claim 9 (canceled) ### Claim 10 (depends on 1) The process of claim 1, wherein the glatiramer acetate related drug substance or drug product of step b) is the same glatiramer acetate related drug substance or drug product of step a), or wherein the glatiramer acetate related drug substance or drug product of step b) is a different glatiramer acetate related drug substance or drug product than the glatiramer acetate related drug substance or drug product of step a). ### Claim 11 (canceled) ### Claim 12 (depends on 1) In a process for producing a drug product comprising a glatiramer acetate related drug substance or a process for releasing a drug product comprising a glatiramer acetate related drug substance, the improvement comprising the steps of: i) characterizing the glatiramer acetate related drug substance or drug product according to the process of claim 1, wherein step e) comprises determining the level of expression of one or more genes selected from the group consisting of Ecm1, Pres1, Pdlim4, Gpr83, Ifng, Il24, LOC100046608, Gm590, Gpr114, Tmie, Rasgrp1, Myo6, Pfkp, Usp18, Arl4c, Als2cl, 2810410P22Rik, Arl5a, Gbp2, Rasgrp1, Ankrd37, Tpi1, 4930583H14Rik, Ifit3, LOC667370, Klhdc1, Cd247, Igfbp4, Oas2, Bcl11b, Fscn1, Ctsg, Mpo, Prtn3, Lyzs, Emr1, Chi3l1, Anxa3, Hp, Lyz2, Lyz, Fer1l3, Sirpa, Cd63, Clec4n, Clec4d, EG433016, Stfa1, Chi3l3 Ngp, S100a8, S100a9, Clecsf9, Saa3, 5033414K04Rik, Slc7a11, Slpi, Cd14, Fpr2, Fcgr3, F10, Gpnmb, Tgfbi, Mmp14, Slc11a1, C3, Gpr84, Acta2, Lcn2, Hmox1, Tsab1, Ccl4, Il2, Inhba, Cxcl1, Serpinb2, Upp1, Gpr109a, Gp38, Il1b, Cxcl2, Il1a, Ccl3, 6720418B01Rik, 5830496L11Rik, Cd8b1, Fcgrt, LOC385615 and Scml4; determining the level of expression of one or more genes selected from the group consisting of the genes presented in Table 8; determining the level of expression of one or more genes selected from the group consisting of the genes presented in Table 10; determining the level of expression of one or more genes selected from the group consisting of FoxP3, GPR83, CD14, TLR2, IFNG, CD40 and IL1B; determining the level of expression of one or more genes selected from the group consisting of the genes presented in Table 12; or determining gene set enrichment analysis for genes associated with at least one cell type selected from the group consisting of FoxP3+ CD4+ T cells, CD4+ T cells CD8+ T cells, gamma delta T cells, natural killer T cells, CD4+ CD8+ T cells, macrophage cells, monocyte cells stromal cells, multi-lineage progenitor cells, dendritic cells, fibroblastic reticular cells, fibroblasts and granulocytes; and; ii) discarding the batch of the glatiramer acetate related drug substance as unacceptable for inclusion in the drug product or discarding the batch of the glatiramer acetate related drug product as unacceptable for release if the level of expression of a gene selected from the group consisting of Ecm1, Pres1, Pdlim4, Gpr83, Ifng, Il24, LOC100046608, Gm590, Gpr114, Tmie, Rasgrp1, Myo6, Pfkp, Usp18, Arl4c, Als2cl, 2810410P22Rik, Arl5a, Gbp2, Rasgrp1, Ankrd37, Tpi1, 4930583H14Rik, Ifit3, LOC667370, Klhdc1, Cd247, Igfbp4, Oas2 Bcl11b, 6720418B01Rik, 5830496L11Rik, Cd8b1, Fcgrt, LOC385615 and Scml4 is decreased relative to a reference standard or if the level of expression of a gene selected from the group consisting of Fscn1, Ctsg, Mpo, Prtn3, Lyzs, Emr1, Chi3l1, Anxa3, Hp, Lyz2, Lyz, Fer1l3, Sirpa, Cd63, Clec4n, Clec4d, EG433016, Stfa1, Chi3l 3 Ngp, S100a8, S100a9, Clecsf9, Saa3, 5033414K04Rik, Slc7a11, Slpi, Cd14, Fpr2, Fcgr3, F10, Gpnmb, Tgfbi, Mmp14, Slc11a1, C3, Gpr84, Acta2, Lcn2, Hmox1, Tsab1, Ccl4, Il2, Inhba, Cxcl1, Serpinb2, Upp1, Gpr109a, Gp38, Il1b, Cxcl2, Il1a, and Ccl3, is increased relative to a reference standard; discarding the batch of the glatiramer acetate related drug substance as unacceptable for inclusion in the drug product if the level of expression of a gene selected from the group consisting of the genes presented in Table 8 is not substantially identical to the level of expression of a reference standard; discarding the batch of the glatiramer acetate related drug substance as unacceptable for inclusion in the drug product if the level of expression of a gene selected from the group consisting of the genes presented in Table 10 is not substantially identical to the level of expression of a reference standard; discarding the batch of the glatiramer acetate related drug substance as unacceptable for inclusion in the drug product if the level of expression of a gene selected from the group consisting of GPR83, IFNG and Foxp3 is decreased or if the level of expression of a gene selected from the group consisting of CD14, CD40, TLR2 and IL1B is increased; discarding the batch of the glatiramer acetate related drug substance as unacceptable for inclusion in the drug product if the level of expression of a gene selected from the group consisting of the genes identified in Table 12 as FoxP3+ T cell genes is decreased or if the level of expression of a gene selected from the group consisting of the genes identified in Table 12 as macrophage genes and the genes identified in Table 12 as monocyte genes is increased; or discarding the batch of the glatiramer acetate related drug substance as unacceptable for inclusion in the drug product if gene set enrichment analysis indicates downregulation or a lack of upregulation for genes associated with at least one cell type selected from the group consisting of FoxP3+ CD4+ T cells, CD4+ T cells CD8+ T cells, gamma delta T cells, natural killer T cells and CD4+ CD8+ T cells or if gene set enrichment analysis indicates upregulation or a lack of downregulation for genes associated with at least one cell type selected from the group consisting of macrophage cells, monocyte cells stromal cells, multi-lineage progenitor cells, dendritic cells, fibroblastic reticular cells, fibroblasts and granulocytes. ### Claim 13 (depends on 1) In a process for producing a drug product comprising a glatiramer acetate related drug substance substance or a process for releasing a drug product comprising a glatiramer acetate related drug substance, the improvement comprising the steps of: i) characterizing the glatiramer acetate related drug substance or drug product according to the process of claim 1, wherein step e) comprises determining the level of expression of at least one gene selected from the group consisting of Foxp3, Il2, Il1a, Il1b, C3, S100a8, S100a9, Cxcl2, Cxcl3, Ccl4, Ccl3 and Cd14; ii) discarding the batch of the glatiramer acetate related drug substance as unacceptable for inclusion in the drug product or discarding the batch of the glatiramer acetate related drug product as unacceptable for release if the level of expression of FoxP3 is decreased relative to a reference standard or if the level of expression of at least one gene selected from the group consisting of Il2, Il1a, Il1b, C3, S100a8, S100a9, Cxcl2, Cxcl3, Ccl4, Ccl3 and Cd14 is increased relative to a reference standard. ### Claim 14 (depends on 2) In a process for producing a drug product comprising a glatiramer acetate related drug substance substance or a process for releasing a drug product comprising a glatiramer acetate related drug substance, the improvement comprising the steps of: i) characterizing the glatiramer acetate related drug substance or drug product according to the process of claim 2, wherein step e) comprises determining the level of biological activity of the cells of step c) selected from the group consisting of, immune response to antigen presenting cells, differentiation of effector lymphocytes, suppression of T lymphocytes, activation of Foxp3 positive regulatory T cells, expansion of mononuclear leukocytes, proliferation of T lymphocytes, expansion of lymphocytes, differentiation of naïve lymphocytes, inflammatory response, adhesion of immune cells, cell movement, migration of cells, chemotaxis of cells, cell movement of phagocytes, chemotaxis of monocytes, cell movement of monocytes and fever; ii) discarding the batch of the glatiramer acetate related drug substance as unacceptable for inclusion in the drug product or discarding the batch of the glatiramer acetate related drug product as unacceptable for release if the level of biological activity selected from the group consisting of immune response to antigen presenting cells, differentiation of effector lymphocytes, suppression of T lymphocytes and activation of Foxp3 positive regulatory T cells is decreased relative to a reference standard or if the level of biological activity selected from the group consisting of expansion of mononuclear leukocytes, proliferation of T lymphocytes, expansion of lymphocytes, differentiation of naïve lymphocytes, inflammatory response, adhesion of immune cells, cell movement, migration of cells, chemotaxis of cells, cell movement of phagocytes, chemotaxis of monocytes, cell movement of monocytes and fever is increased relative to a reference standard. ### Claim at position 15 15-17. (canceled) ### Claim 18 A method of identifying suboptimal activity of a glatiramer acetate related drug substance or drug product comprising the steps of: a) administering a glatiramer acetate related drug substance or drug product to a rodent; b) determining the level of biological activity of the rodent selected from the group consisting of, immune response to antigen presenting cells, differentiation of effector lymphocytes, suppression of T lymphocytes, activation of Foxp3 positive regulatory T cells, expansion of mononuclear leukocytes, proliferation of T lymphocytes, expansion of lymphocytes, differentiation of naïve lymphocytes, inflammatory response, adhesion of immune cells, cell movement, migration of cells, chemotaxis of cells, cell movement of phagocytes, chemotaxis of monocytes, cell movement of monocytes and fever, or determining the level of expression in the rodent of one or more genes selected from the group consisting of Ecm1, Pres1, Pdlim4, Gpr83, Ifng, Il24, LOC100046608, Gm590, Gpr114, Tmie, Rasgrp1, Myo6, Pfkp, Usp18, Arl4c, Als2cl, 2810410P22Rik, Arl5a, Gbp2, Rasgrp1, Ankrd37, Tpil, 4930583H14Rik, Ifit3, LOC667370, Klhdc1, Cd247, Igfbp4, Oas2, Bcl11b, Fscn1, Ctsg, Mpo, Prtn3, Lyzs, Emr1, Chi3l1, Anxa3, Hp, Lyz2, Lyz, Fer1l3, Sirpa, Cd63, Clec4n, Clec4d, EG433016, Stfa1, Chi3l3 Ngp, S100a8, S100a9, Clecsf9, Saa3, 5033414K04Rik, Slc7a11, Slpi, Cd14, Fpr2, Fcgr3, F10, Gpnmb, Tgfbi, Mmp14, Slcllal, C3, Gpr84, Acta2, Lcn2, Hmox1, Tsab1, Ccl14, Il2, Inhba, Cxcl1, Serpinb2, Upp1, Gpr109a, Gp38, Il1b, Cxcl2, Il1a, Ccl3, 6720418B01Rik, 5830496L11Rik, Cd8b1, Fcgrt, LOC385615 and Scml4; determining the level of expression of one or more genes selected from the group consisting of the genes presented in Table 8; determining the level of expression of one or more genes selected from the group consisting of the genes presented in Table 10; determining the level of expression of one or more genes selected from the group consisting of FoxP3, GPR83, CD14, TLR2, IFNG, CD40 and IL1B; determining the level of expression of one or more genes selected from the group consisting of the genes presented in Table 12; or determining gene set enrichment analysis for genes associated with at least one cell type selected from the group consisting of FoxP3+ CD4+ T cells, CD4+ T cells CD8+ T cells, gamma delta T cells, natural killer T cells, CD4+ CD8+ T cells, macrophage cells, monocyte cells stromal cells, multi-lineage progenitor cells, dendritic cells, fibroblastic reticular cells, fibroblasts and granulocytes; and c) identifying the glatiramer acetate related drug substance or drug product as causing a suboptimal activity if the level of biological activity selected from the group consisting of immune response to antigen presenting cells, differentiation of effector lymphocytes, suppression of T lymphocytes and activation of Foxp3 positive regulatory T cells is decreased relative to a reference standard or if the level of biological activity selected from the group consisting of expansion of mononuclear leukocytes, proliferation of T lymphocytes, expansion of lymphocytes, differentiation of naïve lymphocytes, inflammatory response, adhesion of immune cells, cell movement, migration of cells, chemotaxis of cells, cell movement of phagocytes, chemotaxis of monocytes, cell movement of monocytes and fever is increased relative to a reference standard, or identifying the glatiramer acetate related drug substance or drug product as causing a suboptimal activity if the level of expression of a gene selected from the group consisting of Ecm1, Pres1, Pdlim4, Gpr83, Ifng, Il24, LOC100046608, Gm590, Gpr114, Tmie, Rasgrp1, Myo6, Pfkp, Usp18, Arl4c, Als2cl, 2810410P22Rik, Arl5a, Gbp2, Rasgrp1, Ankrd37, Tpi1, 4930583H14Rik, Ifit3, LOC667370, Klhdc1, Cd247, Igfbp4, Oas2 Bcl11b, 6720418B01Rik, 5830496L11Rik, Cd8b1, Fcgrt, LOC385615 and Scml4 is decreased relative to a reference standard or if the level of expression of a gene selected from the group consisting of Fscn1, Ctsg, Mpo, Prtn3, Lyzs, Emr1, Chi3l1, Anxa3, Hp, Lyz2, Lyz, Fer1l3, Sirpa, Cd63, Clec4n, Clec4d, EG433016, Stfa1, Chi3l3 Ngp, S100a8, S100a9, Clecsf9, Saa3, 5033414K04Rik, Slc7a11, Slpi, Cd14, Fpr2, Fcgr3, F10, Gpnmb, Tgfbi, Mmp14, Slc11a1, C3, Gpr84, Acta2, Lcn2, Hmox1, Tsab1, Ccl4, Il2, Inhba, Cxcl1, Serpinb2, Upp1, Gpr109a, Gp38, Il1b, Cxcl2, Il1a, and Ccl3, is increased relative to a reference standard; identifying the glatiramer acetate related drug substance or drug product as causing a suboptimal activity if the level of expression of a gene selected from the group consisting of the genes presented in Table 8 is not substantially identical to the level of expression of a reference standard; identifying the glatiramer acetate related drug substance or drug product as causing a suboptimal activity if the level of expression of a gene selected from the group consisting of the genes presented in Table 10 is not substantially identical to the level of expression of a reference standard; identifying the glatiramer acetate related drug substance or drug product as causing a suboptimal activity if the level of expression of a gene selected from the group consisting of GPR83, IFNG and Foxp3 is decreased or if the level of expression of a gene selected from the group consisting of CD14, CD40, TLR2 and IL1B is increased; identifying the glatiramer acetate related drug substance or drug product as causing a suboptimal activity if the level of expression of a gene selected from the group consisting of the genes identified in Table 12 as FoxP3+ T cell genes is decreased or if the level of expression of a gene selected from the group consisting of the genes identified in Table 12 as macrophage genes and the genes identified in Table 12 as monocyte genes is increased; or identifying the glatiramer acetate related drug substance or drug product as causing a suboptimal activity if gene set enrichment analysis indicates downregulation or a lack of upregulation for genes associated with at least one cell type selected from the group consisting of FoxP3+ CD4+ T cells, CD4+ T cells CD8+ T cells, gamma delta T cells, natural killer T cells and CD4+ CD8+ T cells or if gene set enrichment analysis indicates upregulation or a lack of downregulation for genes associated with at least one cell type selected from the group consisting of macrophage cells, monocyte cells stromal cells, multi-lineage progenitor cells, dendritic cells, fibroblastic reticular cells, fibroblasts and granulocytes thereby identifying suboptimal activity of a glatiramer acetate related drug substance or drug product. ### Claim 19 (canceled) ### Claim 20 (depends on 18) The method of claim 18, wherein the level of expression is determined in the blood. ### Claim 21 (depends on 20) The method of claim 20, wherein the level of expression is determined in PBMCs. ### Claim 22 (depends on 18) The method of claim 18, wherein the reference standard is the level of expression prior to administration of the glatiramer acetate related drug substance or drug product or the level of expression after administration of glatiramer acetate drug substance or drug product. ### Claim 23 (canceled) ### Claim 24 (depends on 4) The process of claim 4, wherein the rodent is a mouse, wherein the rodent is a mouse and the mouse is a female (SJL×BALB/C) F1 mouse and/or wherein the rodent is a mouse and the mouse is about 8 to about 12 weeks old. ### Claim at position 23 25-26. (canceled) ### Claim 27 (depends on 1) The process of claim 1, wherein the primary culture is a culture of spleen cells or a culture of lymph node cells. ### Claim 28 (canceled) ### Claim 29 (depends on 27) The process of claim 27, wherein the primary culture is a culture of spleen cells and wherein the culture of spleen cells is prepared about 3 days after immunization. ### Claim 30 (depends on 1) The process of claim 1, wherein the incubation of step d) is for about 24 hours. ### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30) The process or method of any one of claims 1-30, wherein the glatiramer acetate related drug substance is a glatiramoid or wherein the glatiramer acetate related drug product comprises a glatiramoid, or wherein the glatiramer acetate related drug substance is a glatiramoid other than glatiramer acetate drug substance or wherein the glatiramer acetate related drug product comprises a glatiramoid other than glatiramer acetate drug substance. ### Claim at position 29 32-42. (canceled) ### Claim 43 (depends on 12) The process of claim 12, wherein the reference standard is medium.